C-Reactive Protein in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy and Relationship with Ventricular Tachycardia

被引:30
作者
Bonny, Aime [1 ]
Lellouche, Nicolas [2 ]
Ditah, Ivo [3 ]
Hidden-Lucet, Francoise [4 ]
Yitemben, Martial T. [5 ]
Granger, Benjamin [6 ]
Larrazet, Fabrice [1 ]
Frank, Robert [4 ]
Fontaine, Guy [4 ]
机构
[1] Hop St Camille, Serv Cardiol, 2 Rue Peres Camilliens, F-94366 Bry Sur Marne, France
[2] Hop Henri Mondor, Fed Cardiol, F-94010 Creteil, France
[3] Wayne State Univ, Dept Internal Med, Detroit, MI 48202 USA
[4] Hop La Pitie Salpetriere, Unite Rythmol, F-75651 Paris 13, France
[5] Ctr Hosp Le Cateau, Serv Med, F-59360 Le Cateau Cambresis, France
[6] Hop La Pitie Salpetriere, Dept Biostat, F-75651 Paris 13, France
关键词
D O I
10.4061/2010/919783
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The relationship between C-reactive protein (CRP) elevation and ventricular tachycardia (VT) in arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is unclear. Methods and Results. In 91 consecutive patients with either ARVD/C with or without VT (cases) or idiopathic right ventricular outflow tract (RVOT) tachycardia (controls), blood sampling were taken to determine CRP levels. In ARVD/C patients with VT, we analyzed the association between VT occurrences and CRP level. Sixty patients had ARVD/C, and 31 had idiopathic RVOT VT. Patients with ARVD/C had a significant higher level of CRP compared to those with RVOT VT (3.5 +/- 4.9 versus 1.1 +/- 1.2mg/l, P = .0004). In ARVD/C group, 77%, (n = 46) patients experienced VT. Of these, 37% (n = 17) underwent blood testing for CRP within 24 h after the onset of VT and the remaining 63% (n = 29) after 24 h of VT reduction. CRP level was similar in ARVD/C patients with or without documented VT (3.6 +/- 5.1mg/l versus 3.1 +/- 4.1mg/l, P = .372). However, in patients with ARVD/C and documented VT, CRP was significantly higher when measured within 24 hours following VT in comparison to that level when measured after 24 h (4.9 +/- 6.2mg/l versus 3.0 +/- 4.4mg/l, P = .049). Conclusion. Inflammatory state is an active process in patients with ARVD/C. Moreover, there is a higher level of CRP in patients soon after ventricular tachycardia, and this probably tends to decrease after the event.
引用
收藏
页数:7
相关论文
共 32 条
[1]   How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH [J].
Anker, SD ;
Coats, AJS .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2002, 86 (2-3) :123-130
[2]   Arrhythmogenic right ventricular cardiomyopathy - Dysplasia, dystrophy, or myocarditis? [J].
Basso, C ;
Thiene, G ;
Corrado, D ;
Angelini, A ;
Nava, A ;
Valente, M .
CIRCULATION, 1996, 94 (05) :983-991
[3]   Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure [J].
Bozkurt, B ;
Torre-Amione, G ;
Warren, MS ;
Whitmore, J ;
Soran, OZ ;
Feldman, AM ;
Mann, DL .
CIRCULATION, 2001, 103 (08) :1044-1047
[4]  
Charles-Schoeman C, 2007, J RHEUMATOL, V34, P1459
[5]   Histologic findings in patients with clinical and instrumental diagnosis of sporadic arrhythmogenic right ventricular dysplasia [J].
Chimenti, C ;
Pieroni, M ;
Maseri, A ;
Frustaci, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :2305-2313
[6]   Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator [J].
Chiu, JH ;
Abdelhadi, RH ;
Chung, MK ;
Gurm, HS ;
Marrouche, NF ;
Saliba, WI ;
Natale, A ;
Martin, DO .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (04) :490-491
[7]   Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial [J].
Chung, ES ;
Packer, M ;
Lo, KH ;
Fasanmade, AA ;
Willerson, JT .
CIRCULATION, 2003, 107 (25) :3133-3140
[8]   Medical Progress: Myocarditis. [J].
Cooper, Leslie T., Jr. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (15) :1526-1538
[9]   Arrhythmogenic right ventricular dysplasia/cardiomyopathy - Need for an international registry [J].
Corrado, D ;
Fontaine, G ;
Marcus, FI ;
McKenna, WJ ;
Nava, A ;
Thiene, G ;
Wichter, T .
CIRCULATION, 2000, 101 (11) :E101-E106
[10]   Arrhythmogenic right ventricular cardiomyopathy: diagnosis, prognosis, and treatment [J].
Corrado, D ;
Basso, C ;
Thiene, G .
HEART, 2000, 83 (05) :588-595